Evidence map›Paper›PMID 38021464›Full record

ArticleGlomerular diseases

Cure Glomerulonephropathy Pathology Classification and Core Scoring Criteria, Reproducibility, and Clinicopathologic Correlations.

Matthew B Palmer, Virginie Royal, J Charles Jennette, Abigail R Smith, Qian Liu, Josephine M Ambruzs, Nicole K Andeen, Vivette D D'Agati, Agnes B Fogo, Joseph Gaut and 12 more

Abstract read
In one paragraph

Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Matthew B PalmerDepartment of Pathology, University of Pennsylvania, Philadelphia, PA, USA.
Virginie RoyalDepartment of Pathology, Hospital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada.
J Charles JennetteDepartment of Pathology, University of North Carolina Kidney Center, Chapel Hill, NC, USA.
Abigail R SmithArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Qian LiuArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Josephine M AmbruzsArkana Laboratories, Little Rock, AR, USA.
Nicole K AndeenDepartment of Pathology, Oregon Health and Science University, Portland, OR, USA.
Vivette D D'AgatiDepartment of Pathology, Columbia University, New York, NY, USA.
Agnes B FogoDepartment of Pathology, Vanderbilt University, Nashville, TN, USA.
Joseph GautDepartment of Pathology, Washington University, St. Louis, MO, USA.
Rasheed A GbadegesinDivision of Nephrology, Duke Children's Hospital Medical Center, Durham, NC, USA.
Larry A GreenbaumDivision of Nephrology, Department of Pediatrics, Emory University, Atlanta, GA, USA.
Jean HouDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Margaret E HelmuthArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Richard A LafayetteDivision of Nephrology, Department of Medicine, Stanford University, Stanford, CA, USA.
Helen LiapisNephrology Center, Ludwig Maximilian University, Munich, Germany.
Bruce RobinsonArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Michael B StokesDepartment of Pathology, Columbia University, New York, NY, USA.
Katherine TwombleyDivision of Nephrology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
Hong YinPathology, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Cynthia C NastDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
CureGN Consortium

Funding

CureGNU24DK100845 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CRYSTAL A. GADEGBEKU, Laura H Mariani · 2019 to 2026
$12.1M
The Columbia PCC for CureGN: the Cure Glomerulonephropathy networkU01DK100876 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Andrew Stephen Bomback, ALI G GHARAVI · 2019 to 2026
$8.5M
CureGN-Penn PCCU01DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE B. HOLZMAN · 2019 to 2026
$8.3M
CUREGN 3.0 - Pediatric Nephrology Consortium - PCCU01DK100866 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Laurence A Greenbaum, Jon Klein · 2019 to 2026
$7.7M
CureGN-3: UNCPCCU01DK100867 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Vimal Kumar Derebail, Ronald J Falk · 2019 to 2026
$6.7M
GDPrimeUM1DK100845 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GIPSON, DEBBIE S, KRETZLER, MATTHIAS · 2013 to 2018
$6.4M
Primary Outcomes in Glomerulonephritis Study (PROGRESS)UM1DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HOLZMAN, LAWRENCE B. · 2013 to 2018
$5.8M
Integrative Proteomics & Metabolomics for Pediatric Glomerula Disease BiomarkersUM1DK100866 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GREENBAUM, LAURENCE A, SMOYER, WILLIAM E · 2013 to 2018
$5.5M
Advancing Clinical Research in Primary Glomerular Diseases (UM1)UM1DK100876 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GHARAVI, ALI G · 2013 to 2018
$4.8M
GDCN Clinical Center-Advancing Clinical Research in Primary Glomerular DiseasesUM1DK100867 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FALK, RONALD J · 2013 to 2018
$4.0M
NIDDK NIH HHS U01 DK100846NIDDK NIH HHS U01 DK100866NIDDK NIH HHS U01 DK100867NIDDK NIH HHS U01 DK100876NIDDK NIH HHS U24 DK100845NIDDK NIH HHS UM1 DK100845NIDDK NIH HHS UM1 DK100846NIDDK NIH HHS UM1 DK100866NIDDK NIH HHS UM1 DK100867NIDDK NIH HHS UM1 DK100876
6 · The paper itself

Abstract

Introduction: Cure Glomerulonephropathy (CureGN) is an observational cohort study of patients with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy. We developed a conventional, consensus-based scoring system to document pathologic features for application across multiple pathologists and herein describe the protocol, reproducibility, and correlation with clinical parameters at biopsy. Methods: Definitions were established for glomerular, tubular, interstitial, and vascular lesions evaluated semiquantitatively using digitized light microscopy slides and electron micrographs, and reported immunofluorescence. Cases with curated pathology materials as of April 2019 were scored by a randomly assigned pathologist, with at least 10% of cases scored by a second pathologist. Scoring reproducibility was assessed using Gwet's agreement coefficient (AC)1 statistic and correlations with clinical variables were performed. Results: Of 800 scored biopsies (134 MCD, 194 FSGS, 206 MN, 266 IgA), 94 were scored twice (11.8%). Of 60 pathology features, 46 (76.7%) demonstrated excellent (AC1>0.8), and 12 (20.0%) had good (AC1 0.6-0.8) reproducibility. Mesangial hypercellularity scored as absent, focal, or diffuse had moderate reproducibility (AC1 = 0.58), but good reproducibility (AC1 = 0.71) when scored as absent or focal versus diffuse. The percent glomeruli scored as no lesions had fair reproducibility (AC1 = 0.34). Strongest correlations between pathologic features and clinical characteristics at biopsy included interstitial inflammation, interstitial fibrosis, and tubular atrophy with estimated glomerular filtration rate, foot process effacement with urine protein/creatinine ratio, and active crescents with hematuria. Conclusions: Most scored pathology features showed excellent reproducibility, demonstrating consistency for these features across multiple pathologists. Correlations between certain pathologic features and expected clinical characteristics show the value of this approach for future studies on clinicopathologic correlations and biomarker discovery.

Indexed as

Clinical-pathologic correlationCure GlomerulonephropathyKidney biopsyPathology scoringReproducibility

Identifiers

PMID38021464
PMCPMC10665033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.